SACHI Trial Results: Savolitinib-Osimertinib Combo Improves PFS in MET-Amplified EGFR-Mutated NSCLC
Haleigh BehrmanDr. Shun Lu said savolitinib plus osimertinib offers a potential new chemo-free treatment option for patients after progression on first-line treatment. Read more
IMpower010 Trial Update Highlights Long-Term Benefits of Adjuvant Atezolizumab in Resected NSCLC
Haleigh BehrmanThe updated data and a recently presented exploratory analysis show the benefits varied based on PD-L1 expression, which may be influenced by a variety of genomic alterations. Read more
Dr. Melissa L. Johnson discusses evolving best practices for the operationalization of bispecific T-cell engagers, specifically tarlatamab. Read more
Tarlatamab Emerges as New Standard of Care in Second-Line SCLC, with Significant Gains in OS, PFS
Joy CurzioDr. Charles M. Rudin, who presented data from the DeLLphi-304 trial at ASCO 2025, noted that patient-reported outcomes also showed improvements in common symptoms, including dyspnea and cough, with fewer toxicities of grade 3 or higher. Read more
A Paradigm Shift: Final 5-Year Overall Survival Results from CheckMate 816 in Resectable NSCLC
Haleigh BehrmanDr. Patrick Forde recently presented milestone data from the trial that confirms the benefit of neoadjuvant-only chemoimmunotherapy for the treatment of resectable lung cancer. Read more
Drs. Puneeth Iyengar and Edward Christopher Dee discuss the potential clinical and environmental benefits of hypofractionated radiation therapy, along with the barriers to broader adoption. Read more
Overcoming Resistance Remains a Challenge in Targeting KRAS
Haleigh BehrmanDana-Farber's Dr. Alice Shaw recently explored various combination strategies that show promise in preventing or delaying resistance in this previously undruggable space. Read more
Immune Checkpoint Inhibitors in NSCLC: Do Survival Benefits End if Treatment Does?
Haleigh BehrmanDrs. Mark Awad and Federica Pecci said recent findings suggest some patients with non-small cell lung cancer may experience survival benefits and disease control even after stopping ICI treatment. Read more
The Elephant in the Room: Addressing Oncology’s Carbon Footprint
Haleigh BehrmanFrom travel-related emissions to medical waste, Drs. Puneeth Iyengar and Edward Christopher Dee discuss the environmental impact of radiotherapy. Read more
Up in the Air: A Patient’s Perspective on Navigating Lung Cancer Treatment During One of the Most Devastating Wildfires in US History
Haleigh BehrmanLynn Lieberman was already in a fight against lung cancer, but she faced a second battle when the Los Angeles wildfires spread throughout her community. Read more